EssilorLuxottica to Release New Research Findings at ARVO, Including Five-year Clinical Findings of Essilor Stellest Lenses
EssilorLuxottica to Release New Research Findings at ARVO, Including Five-year Clinical Findings of Essilor Stellest Lenses
Charenton-le-Pont, France (April 22, 2024) – EssilorLuxottica is proud to take part in the 2024 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) in Seattle, USA, where it will present new findings from its studies on advancements in myopia management with Essilor Stellest lenses, and on light management, focusing on topics such as light exposure and photochromic lenses. The full agenda can be viewed in the ARVO pocket guide here.
法国查伦顿勒邦（2024年4月22日）——EssilorLuxottica荣幸地参加在美国西雅图举行的视觉与眼科学研究协会（ARVO）2024年年会，届时它将介绍其关于依视勒Steller镜片近视管理进展以及光线管理研究的新发现，重点关注光曝光和光致变色镜片等主题。完整的议程可以在 ARVO 袖珍指南中查看 这里。
EssilorLuxottica R&D experts will once again be present to showcase their work among their peers. In addition to joining poster presentations and sponsored sessions, attendees will have the opportunity to stop by booth #4815 where they can meet the Group's experts, see what is new at research and development and discover how EssilorLuxottica is shaping the future of vision care through transformative technologies.
EssilorLuxottica研发专家将再次出席，向同行展示他们的作品。除了参加海报展示和赞助会议外，与会者还将有机会在 #4815 号展位停留，在那里他们可以与集团的专家会面，了解研发领域的新进展，并了解EssilorLuxottica如何通过变革性技术塑造视力保健的未来。
The Company will also present the results of a five-year clinical follow-up study of its Essilor Stellest lenses for the first time. The findings strengthen the existing evidence base of the lenses in slowing down myopia progression in children. The data showed that the lenses save one- and three-quarter dioptres of myopia over five years,*1 demonstrating conclusive evidence of their efficacy in slowing down myopia progression in children in the fifth year.
该公司还将首次公布其Essilor Stellest镜头为期五年的临床随访研究结果。这些发现加强了镜片在减缓儿童近视进展方面的现有证据基础。数据显示，这些镜片在五年内可挽救四分之一和四分之三的近视屈光度，*1 这证明了它们在第五年减缓儿童近视进展的确凿证据。
The five-year results will be presented at an EssilorLuxottica sponsored session titled 'Novel approaches and models in myopia management: spectacle lenses with highly aspherical lenslets', on May 5 at 11:00 local time. Dr. Björn Drobe from EssilorLuxottica's R&D team will present the results, along with Prof. Mark Bullimore, MCOptom, PhD, FAAO who will present his insights on predictive models for axial elongation and change in myopia progression.
五年业绩将在EssilorLuxottica赞助的题为 “” 的会议上公布近视管理的新方法和模型：带有高度非球面镜片的眼镜片'，当地时间 5 月 5 日 11:00。来自EssilorLuxottica研发团队的Bjorrn Drobe博士将介绍研究结果，FAAO的mcOpTom博士Mark Bullimore教授将介绍他对轴向伸长和近视进展变化的预测模型的见解。
On May 6 at 10:00 local time, Dr. Yee Ling Wong from EssilorLuxottica's R&D team and Prof. Mark Bullimore will discuss emmetropic eye growth and spectacle lenses with highly aspherical lenslets (HAL) based on findings from a recently published paper. This will be presented at a second sponsored myopia session titled 'Emmetropic eye growth as benchmark for myopia management using spectacle lenses with highly aspherical lenslets'. Essilor Stellest lenses are based on the optical design of HAL lenses. Both sessions will be moderated by Olga Prenat, Head of Medical and Professional Affairs at EssilorLuxottica.
当地时间5月6日上午10点，来自essilorLuxottica研发团队的黄怡玲博士和马克·布利摩尔教授将根据最近发表的一篇论文的研究结果，讨论等向性眼睛生长和带有高度非球面镜片（HAL）的眼镜片。这将在第二届赞助的近视会议上发表，题目是使用带有高度非球面镜片的眼镜镜片将Emmetropic眼睛生长作为近视管理的基准'。Essilor Stellest 镜头基于 HAL 镜头的光学设计。这两次会议都将由EssilorLuxottica医疗和专业事务主管奥尔加·普雷纳特主持。
Norbert Gorny, Chief Scientific Officer at EssilorLuxottica, said, "We are excited to be able to share the latest five-year findings of HAL lenses at ARVO as long-term clinical data is essential to showcase the continued efficacy and performance of the lens in children. As we already know that every dioptre matters, we look forward to sharing scientific data and insights on interventions to address myopia, to bring us all one step closer to protecting the vision of young patients. We will also continue to integrate scientific knowledge with innovative technologies to create the future of myopia control spectacle lenses so that the next generation can see more and be more."
EssilorLuxottica首席科学官诺伯特·戈尔尼说，”我们很高兴能够在ARVO分享HAL镜片的五年最新发现，因为长期临床数据对于展示该镜片对儿童的持续疗效和性能至关重要。我们已经知道每种屈光度都很重要，我们期待分享有关近视干预措施的科学数据和见解，从而使我们所有人离保护年轻患者的视力又近了一步。我们还将继续将科学知识与创新技术相结合，创造近视控制眼镜片的未来，让下一代能够看得更多，看得更多。“
"We are very happy to welcome attendees at our EssilorLuxottica booth where they can discover the company's innovative R&D capabilities and expertise in vision care and meet our R&D and Medical and Professional Affairs teams. The booth will also feature our Digital Infinite Refraction range consisting of Vision-R 800, Vision-S 700 and our specialized biometer, the Myopia Expert 700, designed to monitor myopia progression based on refraction and axial length for effective myopia management," said Olga Prenat, Head of Medical and Professional Affairs at EssilorLuxottica.
“我们非常高兴欢迎与会者光临我们的EssilorLuxottica展位，他们可以在那里了解公司的创新研发能力和视力保健方面的专业知识，并与我们的研发以及医疗和专业事务团队会面。展位还将展出我们的数字无限折射系列，包括Vision-R 800、Vision-S 700和我们的专业生物计量仪近视专家700，旨在根据折射和轴向长度监测近视进展，以有效管理近视，” EssilorLuxottica医疗和专业事务主管奥尔加·普雷纳特说。
Notes
*Compared to the 60-month progression of the Virtual Control Group (predicted average annual decrease in SER by 9.7%, Smotherman C, et al. IOVS 2023;64:ARVO E-Abstract 811).
1 Li X, Huang Y, Liu C, Yin Z, Cui Z, Lim EW, Drobe B, Chen H, Bao J. Myopia control efficacy of Spectacle Lenses with Highly Aspherical Lenslets: results of a 5-year follow-up study. ARVO Annual Meeting, Seattle. 2024. Available at: https://eppro02.ativ.me/web/page.php
注意事项
*与虚拟对照组60个月的进展相比（预计SER每年平均下降9.7％，Smotherman C等人。IOVS 2023; 64: ARVO 电子摘要 811)。
1 Li X、Huang Y、Liu C、Yin Z、Cui Z、Lim EW、Drobe B、Chen H、Bao J. 使用高度非球面镜片的眼镜镜片的近视控制功效：一项为期 5 年的随访研究结果。ARVO 年会，西雅图。2024 年。可在以下网址获得：https://eppro02.ativ.me/web/page.php